Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have
substantially improved anticoagulation therapy for prevention of stroke and systemic …

Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for
stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and …

Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …

Aims Edoxaban treatment for stroke prevention in atrial fibrillation (AF) has mainly been
investigated in randomized controlled trials, and data reflecting clinical practice are limited …

Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for
stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in …

Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and
treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF) …

Introduction: Edoxaban is the last direct oral anticoagulant marketed for the prevention of
stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF …

Aims Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from
cardiovascular complications including cardiovascular death, stroke, and major bleeding. To …

Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for
the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate …